-
公开(公告)号：US08956812B2
公开(公告)日：2015-02-17
申请号：US10585030
申请日：2004-08-23
Applicant: Krishna Murthy Ella , Srinivas Kannappa Vellimedu
Inventor： Krishna Murthy Ella , Srinivas Kannappa Vellimedu
IPC: C12Q1/70 , C12N7/02 , A61K39/00 , A61K39/205 , A61K39/29 , A61K39/02 , G01N1/18 , C07K14/005 , C07K1/36
CPC classification number: C07K14/005 , C07K1/36 , C12N2730/10122 , C12N2760/20122 , C12N2770/32422 , Y10T436/25375
Abstract: A novel process for the purification of recombinant protein expressed as particle is herewith described. In this purification process, the protein is purified by hydrophobic interaction. The interaction of this protein step resulted in an increase in recovery and purity from 15%-80%. The protein further purified has its application in vaccines and pharmaceuticals.
Abstract translation: 本文描述了用于纯化表达为颗粒的重组蛋白的新方法。 在该纯化过程中，通过疏水相互作用来纯化蛋白质。 该蛋白质步骤的相互作用导致15％-80％的回收率和纯度增加。 进一步纯化的蛋白质可用于疫苗和药物。
-
Patent Agency Ranking
2.发明申请公开(公告)号：US20080311216A1
公开(公告)日：2008-12-18
申请号：US11915727
申请日：2006-05-18
Applicant: Krishna Murthy Ella , Srinivas Kannappa Vellimedu
Inventor： Krishna Murthy Ella , Srinivas Kannappa Vellimedu
IPC: A61K35/64 , A61K38/18 , A61K36/9066 , A61P17/02 , A61K36/886
CPC classification number: A61K38/50 , A61K9/0014 , A61K9/0019 , A61K9/06 , A61K9/10 , A61K31/355 , A61K31/375 , A61K31/555 , A61K31/716 , A61K31/728 , A61K35/14 , A61K35/644 , A61K36/185 , A61K36/886 , A61K36/9066 , A61K38/1808 , A61K38/1858 , A61K38/193 , A61K45/06 , A61K2300/00
Abstract: A composition for treating a wound, wherein the composition can comprise therapeutically effective amount of an epidermal growth factor and a physiologically acceptable agent, wherein the physiologically acceptable agent comprises at least one of a stabilizer, a preservative, a thickening agent, carrier/diluent, and optionally pH regulating agent and humectant.
Abstract translation: 一种用于治疗伤口的组合物，其中所述组合物可包含治疗有效量的表皮生长因子和生理学上可接受的试剂，其中所述生理学上可接受的试剂包括稳定剂，防腐剂，增稠剂，载体/稀释剂， 和任选的pH调节剂和保湿剂。
-
3.发明申请公开(公告)号：US20080226614A1
公开(公告)日：2008-09-18
申请号：US11660976
申请日：2004-08-23
CPC classification number: A61K36/064 , A61K9/0095 , A61K9/2081 , A61K35/747 , A61K45/06 , A61K2300/00
Abstract: The present invention describes a eukaryotic based synergistic formulation for gastro-intestinal disorders comprising eukaryolics and adjuncts selected from pharmaceutically and or physiologically acceptable components. The invention also describes the manner in which the eukaryolics are isolated from tropical fruits , The medium used for growing them and the method used to convert the formulation to dispensable forms. The medium comprising Glucose for carbon source, soybean casein dextrose medium (SCDM) for Nitrogen source, MgSo4, KCl, NaCl, (NH)4HPO4 and with microelements like MnSO4, FeSO4, Boric acid and Vitamins, D-Biotin and thiamine HCl ranging from 0.001% to 0.6% and designated as BBIL-SB. The formulation can be effectively used to prevent and or cure gastro intestinal disorders by administering in various forms to the mammals including human suffering there from, in a required quantity.
Abstract translation: 本发明描述了一种用于胃肠疾病的基于真核的协同制剂，其包括选自药学和/或生理上可接受的组分的真核细胞和辅助剂。 本发明还描述了从热带水果中分离真核细胞的方式。用于培养它们的培养基和用于将制剂转化成可分配形式的方法。 包含用于碳源的葡萄糖，用于氮源的大豆酪蛋白葡萄糖培养基（SCDM），MgSo 4，KCl，NaCl，（NH）4HPO 4以及诸如MnSO 4，FeSO 4，硼酸和维生素，D-生物素和硫胺素的微量元素的培养基，其范围从 0.001％至0.6％，称为BBIL-SB。 该制剂可以有效地用于预防和/或治疗胃肠道疾病，其通过以所需数量向哺乳动物施用各种形式，包括患有这些哺乳动物。
-
公开(公告)号：US08754043B2
公开(公告)日：2014-06-17
申请号：US13912103
申请日：2013-06-06
Applicant: Krishna Murthy Ella , Srinivas Kannappa Vellimedu
Inventor： Krishna Murthy Ella , Srinivas Kannappa Vellimedu
IPC: A61K38/18 , C07K14/485
CPC classification number: A61K38/50 , A61K9/0014 , A61K9/0019 , A61K9/06 , A61K9/10 , A61K31/355 , A61K31/375 , A61K31/555 , A61K31/716 , A61K31/728 , A61K35/14 , A61K35/644 , A61K36/185 , A61K36/886 , A61K36/9066 , A61K38/1808 , A61K38/1858 , A61K38/193 , A61K45/06 , A61K2300/00
Abstract: A composition for treating a wound, wherein the composition can comprise therapeutically effective amount of an epidermal growth factor and a physiologically acceptable agent, wherein the physiologically acceptable agent comprises at least one of a stabilizer, a preservative, a thickening agent, carrier/diluent, and optionally pH regulating agent and humectant.
Abstract translation: 一种用于治疗伤口的组合物，其中所述组合物可包含治疗有效量的表皮生长因子和生理学上可接受的试剂，其中所述生理学上可接受的试剂包括稳定剂，防腐剂，增稠剂，载体/稀释剂， 和任选的pH调节剂和保湿剂。
-
5.发明申请公开(公告)号：US20130272999A1
公开(公告)日：2013-10-17
申请号：US13912103
申请日：2013-06-06
Applicant: Krishna Murthy Ella , Srinivas Kannappa Vellimedu
Inventor： Krishna Murthy Ella , Srinivas Kannappa Vellimedu
IPC: A61K38/18 , A61K38/19 , A61K36/886 , A61K36/9066 , A61K36/185 , A61K45/06 , A61K35/14 , A61K31/555 , A61K31/728 , A61K31/716 , A61K31/375 , A61K31/355 , A61K38/50 , A61K35/64
CPC classification number: A61K38/50 , A61K9/0014 , A61K9/0019 , A61K9/06 , A61K9/10 , A61K31/355 , A61K31/375 , A61K31/555 , A61K31/716 , A61K31/728 , A61K35/14 , A61K35/644 , A61K36/185 , A61K36/886 , A61K36/9066 , A61K38/1808 , A61K38/1858 , A61K38/193 , A61K45/06 , A61K2300/00
Abstract: A composition for treating a wound, wherein the composition can comprise therapeutically effective amount of an epidermal growth factor and a physiologically acceptable agent, wherein the physiologically acceptable agent comprises at least one of a stabilizer, a preservative, a thickening agent, carrier/diluent, and optionally pH regulating agent and humectant.
Abstract translation: 一种用于治疗伤口的组合物，其中所述组合物可包含治疗有效量的表皮生长因子和生理学上可接受的试剂，其中所述生理学上可接受的试剂包括稳定剂，防腐剂，增稠剂，载体/稀释剂， 和任选的pH调节剂和保湿剂。
-
公开(公告)号：US08481049B2
公开(公告)日：2013-07-09
申请号：US11915727
申请日：2006-05-18
Applicant: Krishna Murthy Ella , Srinivas Kannappa Vellimedu
Inventor： Krishna Murthy Ella , Srinivas Kannappa Vellimedu
IPC: A61K38/18 , C07K14/485
CPC classification number: A61K38/50 , A61K9/0014 , A61K9/0019 , A61K9/06 , A61K9/10 , A61K31/355 , A61K31/375 , A61K31/555 , A61K31/716 , A61K31/728 , A61K35/14 , A61K35/644 , A61K36/185 , A61K36/886 , A61K36/9066 , A61K38/1808 , A61K38/1858 , A61K38/193 , A61K45/06 , A61K2300/00
Abstract: A composition for treating a wound, wherein the composition can comprise therapeutically effective amount of an epidermal growth factor and a physiologically acceptable agent, wherein the physiologically acceptable agent comprises at least one of a stabilizer, a preservative, a thickening agent, carrier/diluent, and optionally pH regulating agent and humectant.
Abstract translation: 一种用于治疗伤口的组合物，其中所述组合物可包含治疗有效量的表皮生长因子和生理学上可接受的试剂，其中所述生理学上可接受的试剂包括稳定剂，防腐剂，增稠剂，载体/稀释剂， 和任选的pH调节剂和保湿剂。
-
-
-
-
-
Search Results
6
records
(took 0.021 seconds)
